Zacks Research Has Positive Outlook for DNLI Q2 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities researchers at Zacks Research raised their Q2 2025 EPS estimates for Denali Therapeutics in a report released on Tuesday, May 27th. Zacks Research analyst A. Chakraborty now anticipates that the company will post earnings of ($0.77) per share for the quarter, up from their prior estimate of ($0.85). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Denali Therapeutics' Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($3.14) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($3.18) EPS, Q1 2027 earnings at ($0.74) EPS and FY2027 earnings at ($2.86) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter last year, the company posted ($0.68) earnings per share.

Several other brokerages also recently weighed in on DNLI. Morgan Stanley initiated coverage on Denali Therapeutics in a research report on Friday, March 7th. They set an "overweight" rating and a $33.00 price objective for the company. B. Riley reissued a "buy" rating and issued a $35.00 price objective (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Robert W. Baird reduced their price objective on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. William Blair raised Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $33.71.

Denali Therapeutics Stock Up 1.1%

Shares of NASDAQ:DNLI traded up $0.15 during midday trading on Friday, hitting $14.11. The stock had a trading volume of 1,005,888 shares, compared to its average volume of 1,115,950. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33. The business's 50-day simple moving average is $13.84 and its 200-day simple moving average is $18.38. The company has a market cap of $2.05 billion, a P/E ratio of -5.11 and a beta of 1.49.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its stake in Denali Therapeutics by 0.3% during the 4th quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock valued at $3,880,000 after purchasing an additional 497 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after purchasing an additional 885 shares during the last quarter. Knights of Columbus Asset Advisors LLC boosted its holdings in shares of Denali Therapeutics by 2.7% in the first quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company's stock valued at $548,000 after purchasing an additional 1,058 shares during the period. Sterling Capital Management LLC raised its stake in Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in Denali Therapeutics by 277.0% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after buying an additional 1,551 shares in the last quarter. Institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.